BodeyG.P.. Overview of the problem of infections in the immunocompromised host.Am J Med.1985; 79: 56–61.
2.
SicklesE.A., GreeneW.H., WiernikP.H.. Clinical presentation of infection in granulocytopenic patients.Arch Intern Med.1975; 135: 715–719.
3.
FreifeldG.A., WalshT.J., PizzoP.A.. Infections in the cancer patient. In: De VitaVTJr, HellmanS., RosenbergS.A., eds. Cancer: Principles and Practice of Oncology.5th ed.Philadelphia, Pa: Lippincott;1997: 2659–2704.
4.
FeusnerJ., CohenR., O'LearyM.. Use of routine chest radiography in the evaluation of fever in neutropenic pediatric oncology patients.J Clin Oncol.1988; 6: 1699–1702.
5.
KatzJ.A., BashR., RollinsN.. The yield of routine chest radiography in children with cancer hospitalized for fever and neutropenia.Cancer.1991; 68: 940–943.
6.
KoronesD.N., HussongM.R., GullaceM.A.. Routine chest radiography of children with cancer hospitalized for fever and neutropenia: is it really necessary?Cancer.1997; 80: 1160–1164.
7.
DonowitzG.R., HarmanC., PopeT.. The role of the chest roentgenogram in febrile neutropenic patients.Arch Intern Med.1991; 151: 701–704.
8.
TalcottJ.A., SiegelR.D., FinbergR.. Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule.J Clin Oncol.1992; 10: 316–322.
9.
FreifeldA., MarchigianiD., WalshT.. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.N Engl J Med.1999; 341: 305–311.
10.
KernW.V., ComettaA., De BockR.. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. International Antibicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer.N Engl J Med.1999; 341: 312–318.
11.
CostantiniP., CaceresV., EspinosaL.. Risk assessment in cancer patients with febrile neutropenia: a modified Talcott system. Ninth International Symposium on Infections in the Immunocompromised Host, Assisi, Italy. 1996: 002. Abstract.
12.
QuadriT.L., BrownA.E.. Infectious complications in the critically ill patient with cancer.Semin Oncol.2000; 27: 335–346.
HughesW.T., ArmstrongD., BodeyG.P.. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.Clin Infect Dis.1997; 25: 551–573.
15.
MarcusR.E., GoldmanJ.M.. Management of infection in the neutropenic patient.Br Med J (Clin Res Ed).1986; 293: 406–408.
RosenowECIII, WilsonW.R., Cocker-illFRIII. Pulmonary disease in the immunocompromised host.Mayo Clin Proc.1985; 60: 473–487.
20.
RubinR.H., GreeneR.. Clinical approach to the compromised host with fever and pulmonary infiltrates. In: RubinR.H., YoungL.S., eds. Clinical Approach to Infection in the Compromised Host.New York, NY: Plenum Medical Book Co;1994.
21.
KlaterskyJ.. Current attitudes for therapy of febrile neutropenia with consideration to cost-effectiveness.Curr Opin Oncol.1998; 10: 284–290.
22.
HeusselC.P., KauczorH.U., HeusselG.. Early detection of pneumonia in febrile neutropenic patients: use of thin-section CT.AJR Am J Roentgenol.1997; 169: 1347–1353.
23.
OhY.W., EffmannE.L., GodwinJ.D.. Pulmonary infections in immunocompromised hosts: the importance of correlating the conventional radiologic appearance with the clinical setting.Radiology.2000; 217: 647–656.